




Sino-American Pharmaceutical Professionals Association-Greater Philadelphia

2010

SAPA-GP Annual Conference

美中医药开发协会-费城 2010 年会

Turn Challenges into Opportunities in an Evolving Pharmaceutical Industry



Keynote Speakers

Mervyn Turner, PhD

Chief Strategy Officer, Merck & Co., Inc.,
Senior VP, Emerging Markets, MRL

Evan Loh, MD

Senior VP, Development and Strategic Operations,
Biotherapeutics, R&D, Pfizer

Zhi Hong, PhD

Senior VP, Head of Infectious Disease, Centre of
Excellence in Drug Discovery at GSK

Ruiping Dong, MD, PhD

VP, Head of R&D Japan & China, BMS

Mr. Mingde Yu

President, China Pharmaceutical Enterprises Association

Darren Ji, MD, PhD, MBA

CEO, PharmaLegacy

Zhengping Zhu, MD, PhD

VP & Global Head, Protein Sciences & Design
Novartis Biologics

Friday & Saturday, April 30 - May 1, 2010

Manufacturers' Golf and Country Club (Day 1 -April 30)

511 Dreshertown Road, Fort Washington, Pennsylvania 19034

The Learning Center, Temple University Ambler Campus (Day 2 -May 1)

580 Meetinghouse Road, Ambler, Pennsylvania

For Program Details & To Register Online: www.sapa-gp.org

Organizing Co-Chairs

Tsang-Bin Tzeng, PhD

President, SAPA-GP

Jingsong Wang, MD

President-Elect, SAPA-GP

SAPA-GP Annual Conference is a one and half day event featuring senior executives from biotechnology and pharmaceutical companies to discuss current challenges, innovative strategies, and the impact of mergers, acquisitions, and reorganization to the evolving biotech & pharma and industry. In align with the conference theme, a designated career development symposium & job fair will focus on new job opportunities in R&D, outsourcing, business and entrepreneurship in both in the US and in emerging markets, especially China.

The conference will be truly an ideal platform for you to learn, discuss and to networking with senior executives and fellow colleagues in the industry. We look forward to seeing you at the conference! If you are interested in sponsoring this event, please contact Dr. Tao Jiang at jiang@pc-institute.com

Conference Agenda

Friday, April 30, 2010

Career Development Symposium and Job Fair

Manufacturers' Golf and Country Club

511 Dreshertown Road, Fort Washington, Pennsylvania, 19034
(215) 886-3200 www.mg-cc.org

1:00 – 2:00 PM

On-site Registration and Networking

2:00 – 4:20 PM

Career Development Symposium

- Timely and relevant practical tips in how to survive and thrive in today's tough job market
- Roadmap to assist you to navigate your career path both in China and US
- Most valuable guidance from popular coaches at previous SAPA-GP career development workshop
- A unique career development educational opportunity you couldn't afford to miss

Moderators: Tsang-Bin Tzeng, PhD & Laura Hong, MD, PhD

2:00 – 2:20 PM

How to turn a crisis into an opportunity and start one's own business

Allen Reitz, PhD

Co-Founder and CEO, ALS Biopharma, LLC

2:20 – 2:40 PM

Reinventing drug discovery at the Pennsylvania Center for Drug Discovery

Ms. Kathleen Czupich

Director, Pennsylvania Center for Drug Discovery

2:40 – 3:00 PM

Academy's new focus on translating knowledge to innovative drugs

Biao Jiang, PhD

Vice President, Shanghai Advanced Research Institute, Chinese Academy of Sciences

3:00 – 3:20 PM

How to beat the competition in a tough job market

The presentation will be aimed at providing the most benefit to job seekers and giving them guidance how to conduct a targeted job search and positioning themselves for the position of their choice.

- How to build a marketable resume
- Maximizing exposure by utilizing, internet tools and recruitment firms
- Preparing for your moment in the sun, the interview

Christopher Pagotto

President, Veritas Life Science

3:20 – 3:50 PM **Keynote Address** *-You Can Do It in China!*
Life science in China, the past meets the future: Opportunities for you
Darren Ji, MD, PhD, MBA
CEO, PharmaLegacy, Shanghai, China

3:50 – 4:20 PM **Keynote Address** *-You Can Do It Here in the US Too!*
How to advance your career in pharmaceutical industry
Evan Loh, MD
Senior VP, Development and Strategic Operations (DSO), Biotherapeutics, R&D, Pfizer

4:20 – 4:40 PM
Coffee Break

4:40 – 5:30 PM
Career Development Panel Discussion & Job Fair
Moderators: Jingsong Wang, MD & Guosheng Wu, PhD

Panelists:
[Above speakers plus](#)

Zhi Hong, PhD, Senior VP, Head of ID CEDD, GSK
Zhengping Zhu, MD, PhD, VP & Global Head, Protein Sciences & Design, Novartis Biologics
Ruiping Dong, MD, PhD, VP, Head of R&D Japan & China, BMS
Peter Tu, JD, MBA, Chief IP Counsel and Vice President of Legal, Moksha8 Pharmaceuticals
Christopher Pagotto, President, Veritas Life Science
Bob Chandis, Managing Partner, ZRG Partners, Asia Pacific

5:30 – 6:00 PM
Coffee Break, Networking, Exhibit Booth Viewing & Job Fair

Companies with job openings will answer questions from the prospective candidates and offer on-site interviewing



Friday, April 30, 2010

6:00 – 7:30 PM

Opening Keynote & Dinner Reception

SunTen Phytotech Night



Moderators: Joan Shen, MD, PhD. & Weihong Hsing, PhD, JD

Manufacturers' Golf and Country Club
511 Dreshertown Road, Fort Washington, Pennsylvania, 19034
(215) 886-3200 www.mg-cc.org

Invited Guests

All speakers for the conference, &

Mr. David Briel, Executive Director, Office of Direct Investment, Department of Community and Economic Development, Commonwealth of Pennsylvania

Mr. Keyu Peng, Consul General, The Consulate General of the People's Republic of China in New York

Mr. Zhongyin Mao, Director, Office of Science & Technology, The Consulate General of the People's Republic of China in New York

Mr. Dennis M. "Mickey" Flynn, President of Pennsylvania BIO

Ms. Debbie Hart, President of BioNJ

Mr. Bob Dayton, President of Delaware BIO

6:00-6:30 PM

Keynote Address:

Mervyn J. Turner, PhD

Chief Strategy Officer, Merck & Co., Inc.,

Senior VP, Emerging Markets, Merck Research Laboratories

"Go East, young man!"

"Go West, young man, and grow up with the country". So wrote Horace Greeley in an editorial in the New York Tribune in 1865. If he was writing today, he might possibly say "Go East, young man". A large part of the growth of our industry over the next decade is going to occur in the Asia Pacific region. How should the pharmaceutical industry respond to the challenges and opportunities that this change offers?

6:30 – 7:00 PM

SAPA-GP Year in Review & Award Ceremony

7:00 – 7:30 PM

Music Performance by Internationally Renowned Youth Artists

7:30-11:30 PM

Karaoke & Dance Party

Professional DJs are available

All registered dinner attendees & invited guests are welcomed to join this fun & exciting social networking event!



Conference Agenda

Saturday, May 1, 2010

The Learning Center, Temple University Ambler Campus

7:30 – 8:15 AM

On-site Registration and Networking

8:15 AM – 12:30 PM

Morning Session

Emerging Markets & Transformation of Pharma R&D

Moderator: Tsang-Bin Tzeng, PhD (SAPA-GP President 2009 - 2010)

8:15 – 8:30 AM

Welcome and Opening Remarks

Tsang-Bin Tzeng, PhD, SAPA-GP President

Keynote Speakers

8:30 – 9:00 AM

Health care reform in China and its impact on pharmaceutical industry

Mr. Mingde Yu

President, China Pharmaceutical Enterprises Association

9:00 – 9:30 AM

Opportunities and challenges of drug development in North Asia

Ruiping Dong, MD, PhD

VP, Head of R&D Japan & China, Bristol-Myers Squibb

9:30 – 10:00 AM

Differences between marketing in China and the West

- Impacts of Chinese culture and the Chinese health care environment
- Leading organizations in China
- Using cultural knowledge for business advantage

Mr. Wim Vandenhouwele

Executive Director, Global Vaccines Commercial Development, Merck & Co. Inc.

Former Executive Director, Marketing, Strategy and HIV-AIDS Public-Private Partnership for Merck Sharp & Dohme (China) Ltd.

10:00 – 10:15 AM

Coffee Break

10:15 – 10:45 AM

Perspect of Infectious Diseases R&D

Zhi Hong, PhD

Senior VP, Head of Infectious Diseases Center of Excellence for Drug Discovery, GSK

10:45 – 11:15 AM

Development of next generation antibody-based therapeutics: the present, the challenges and future perspectives

Zhenping Zhu, MD, PhD

VP & Global Head, Protein Sciences & Design, Novartis Biologics

11:15 – 11:35 AM

Leveraging discovery assets toward pharma-market exclusivity in the United States

Mr. Patrick Higgins

Member of Eckert Seamans

11:35 – 11:50 AM

Coffee Break & Snacks

11:50- 12:30 PM

Chinese Pharmaceutical Industry Leaders' Forum

Moderator: Peter Luo, PhD

The forum will cover the following topics:

- Current status and trend of Chinese pharma industry
- Health care reform and its impact on pharma industry
- Challenges for globalization
- Global pharma R&D trend and impact on Chinese industry
- Opportunities for collaboration & partnership with companies in the US

Panelists:

Mr. Mingde Yu, President, China Pharmaceutical Enterprises Association

Ruiping Dong, MD, PhD, VP, Head of R&D Japan & China, BMS

Zhenping Zhu, MD, PhD, VP & Global Head, Protein Sciences & Design, Novartis Biologics

Mr. Zhang Zegong, Deputy Director, Beijing Pharma and Biotech Center

Jack Zheng, PhD, CEO, eVenus Pharmaceutical Laboratories Inc; VP, Jiangsu Hengrui Medicine, Co. 江苏恒瑞

Isaac Liu, Ph.D (Invited), CEO, Hisun Pharmaceuticals USA Inc. 海正药业

12:30 PM – 1:30 PM

Lunch

Complimentary to All Registered Attendees and Guest Speakers

1:30 PM – 6:05 PM
Afternoon Session

1:30 – 3:30 PM

Merger and Acquisition, Intellectual Properties, and Novel R&D Models

Moderators: Weihong Hsing, PhD, JD, and Augustine Yee, JD

1:30 – 2:00 PM

Navigating the IP landscape

Peter Tu, JD, MBA

Chief IP Counsel and Vice President of Legal, Moksha8 Pharmaceuticals

2:00 – 2:30 PM

Biosimilars: Opportunities and challenges in an evolving field

Lily Zou, PhD, MBA

Senior Director, Business Development and Licensing at Sandoz Inc

2:30 – 3:00 PM

Partnering with Beijing Government to build a \$100M joint venture for China's first US cGMP facility to support the global biologic R&D

Julius Li, MBA

CEO, AutekBio

3:00 – 3:30 PM

How to minimize risk of intellectual property litigation when terminating employment

Mr. Ronald L. Panitch

Managing Partner, Panitch Schwarze Belisario & Nadel LLP

3:30 – 4:00 PM

Coffee Break & Networking

4:00 – 6:00 PM

CRO Forum

Moderators: Joan Shen, MD, PhD, Sean Zhang, MD

Panelists:

Hui Cai, PhD, MBA, VP, Wuxi AppTec

Ningning Ma, PhD, VP, Sino Biological Inc.

Dongmei Wang, PhD, VP, Frontage Laboratories

Shifang Zhang, PhD, Senior Director, Genewiz

Huiqun Xia, Assist Director, Shanghai Clinical Research Center

Larry Wang, PhD, President, GeneScript

Darren Ji, MD, PhD, MBA, CEO, PharmaLegacy

Ray Yin, PhD, CEO, ANP Technologies

Wen Chen, MBA, VP, Tigermed

Harry Li, PhD, President & CEO, Wilmington Pharma Tech

6:00 – 6:05 PM

Closing Remarks

Jingsong Wang, MD, SAPA-GP President 2010-2011

Bio for Speaker & Panelist

Alphabetical order based on last name



Hui Cai, PhD, MBA

Dr. Hui Cai is Vice President of Business Development at WUXI AppTec, a leading global pharmaceutical R&D service organization listed on New York Stock Exchange (NYSE: WX) with 4200 employees in China and US. She brought to WX with a broad portfolio of expertise in strategic planning, business development, and portfolio management as President of Inflexion BioPartners and Vice President of Corporate Development at HUYA Bioscience. Prior to that, Dr.Cai spent ten years at Johnson & Johnson Pharmaceutical Research and Development, co-leading multiple small molecule drug discovery programs. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents.

Dr. Cai was appointed by the Mayor of San Diego, in 2002, and has served as a Commissioner at City of San Diego Science and Technology Commission. She is currently Chairwoman of SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association), and 2009 Chair of the San Diego section of the American Chemical Society.

Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a recipient of the distinguished DLA Piper - Athena FlexMBA Scholarship.

Wen Chen, MBA

Mr. Wen Chen joined Tigermed as Vice President of Business Development in May, 2009. Before this appointment, he oversaw operation and business development at HD Biosciences, a Shanghai-based preclinical CRO. In 2008, he led the effort to raise Series A financing for HDB from Pfizer, Lilly Asia Venture and Morningside Technology. From 2005 to 2007, Wen was chief representative then executive VP of China operation for Huya Biosciences International, a San Diego biotech company dedicating to license proprietary NCEs originated from China for global product development. He was instrumental in sourcing, negotiation the licensing and transferring 2 proprietary Chinese NCEs to the States for FDA IND filings. Mr. Chen received his undergraduate degree in biochemistry from Purdue University in Indiana and graduate training in immunology and oncology at Washington University School of Medicine and Harvard University Beth Israel Medical Center. He then worked at Amgen in Thousand Oaks. He received his MBA from Durham University in UK.

Ms. Kathleen M. Czupich

Ms. Kathleen M. Czupich has over 20 years experience in business development and was the founding administrator for the IHVR and the Center. Ms. Czupich managed the financial and administrative aspects of the \$7.9 million grant to construct the Center and the resulting building project totaling more than \$14 million. She was also instrumental in the negotiation, financing and purchase of the adjacent building, expanding the PBC to 115,000 square feet. Currently, in her role as Director of the PCDD, Ms. Czupich works on business development, grants administration, and management for early stage technology based businesses.



Ruiping Dong, PhD, MD

Ruiping Dong, MD, PhD is currently Vice President, Head of R&D Japan & China. Ruiping joined BMS served as VP of R&D Japan and various leadership roles with increased responsibilities in Asia-Pacific region since 2004. Prior to that, Ruiping was with AstraZeneca as medical advisor, product team lead, Head of clinical oncology. Before joining industry, he was a research fellow at Dana-Farber Cancer Institute, Harvard Medical School. Ruiping obtained his MD degree in Jiangxi Medical School in China, and PhD degree in Kyushu University of Medical School in Japan.



Mr. Patrick Higgins

Patrick Higgins' works closely involves building and preserving market exclusivity in the Pharmaceutical industry. His practice focuses on identifying and evaluating discovery assets toward developing, maintaining and enforcing exclusivity employing patent law and FDA regulatory tools. His practice closely monitors relevant drug substance facts, freedom to operate, IP exclusivity, relevant scope, term, jurisdiction, ownership, validity, enforceability, regulatory issues, as well as the evaluation and control of risk and antitrust exposure in ANDA, litigation, for example.

Prior to joining Eckert Seamans, Patrick was a partner at an international law firm in Princeton. Before that he served as senior patent counsel for a major pharmaceutical company, where he was responsible for strategic portfolio development, risk evaluation and due diligence matters. Before entering law school, he worked as a research scientist at a major pharmaceutical company where he was awarded the Global Director of Research Award.



Zhi Hong, PhD

Dr. Zhi Hong is Senior Vice President of the Infectious Diseases Centre of Excellence in Drug Discovery at GlaxoSmithKline (GSK). He has global responsibility for GSK's Antiviral and Antibacterial discovery effort. He has led the company's effort in the virtualization of drug discovery through strategic alliances with a number of external biotech companies including Anacor, Galapagos, Santaris and Mpex. Dr. Hong was instrumental in GSK's acquisition of Genelabs Technologies, Inc., a California-based biotech firm with an extensive HCV portfolio. He also played a key role in the execution of a license agreement granting GSK exclusive worldwide rights to a Phase II compound from Idenix Pharmaceuticals for the treatment of HIV/AIDS. Dr. Hong is also a

Board Member of Anacor Pharmaceuticals as well as ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline and Pfizer.

Prior to GSK, he was the Chief Scientific Officer and Executive Vice President of Research at Ardea Biosciences, a publicly traded biotech company in California. Before that, he was the Vice President of Research at Valeant Pharmaceuticals International. During his drug discovery career in the pharmaceutical industries, Dr. Hong and his teams successfully delivered many drug candidates into the clinics. As a scientist, he is well respected as an opinion leader in the field of antiviral research. As an executive, he has played a leading role in strategic realignment, therapeutic rebalancing and associated change management.

Dr. Hong has many years of experience in drug discovery and product development. He received a Bachelor of Science degree from Fudan University at Shanghai, China, and his Ph.D from the State University of New York at Buffalo. He has authored/co-authored more than 100 research publications and given numerous lectures/speeches at various meetings. He has more than 40 issued and/or published patents.



Darren Ji, MD, PhD, MBA

Dr. Darren Ji is the CEO and founder of PharmaLegacy Laboratories, a leading preclinical pharmacology CRO (contract research organization) based in Shanghai. PharmaLegacy is a fast-growing biotech company and provides services to many of the top biopharmaceutical companies worldwide. Previously, Darren was the Director of Bioscience Business Development – East Asia for the Procter & Gamble Company. Darren successfully engineered multiple significant bioscience transactions between P&G and entities in the East Asia region. Darren is a Board Director of the BayHelix Group and was the President of the International Chinese Hard Tissue Society. Darren obtained his MD from China Medical University, China; a PhD from the University of Sheffield, UK; and an MBA from University of Chicago.



Biao Jiang, PhD

中国科学院上海高等研究院筹备委员会主席，中国科学院上海有机化学所前任副所长

Dr. Jiang is the President of preparatory committee of Shanghai Advanced Research Institute, CAS. He joined SARI in 2009, following a successful 14-year career in Shanghai Institute of Organic Chemistry as Deputy Director. While in SIOC, his research interests centered on developing new methodology towards organic synthesis, total synthesis of natural products and organofluorine chemistry. He has more than 100 publications and 30 patents to his name.

He was involved in many national and international initiatives and has been recognized as Shanghai Top Ten Youth Star of Science and Technology in 1996 and Shanghai Top Ten Outstanding Youth in 1997. Many other awards include Eli Lilly Research Excellence Award in China in 2006.

Dr. Jiang Received M.Sc from Lanzhou University and completed his PhD and post doctor at Shanghai Institute of Organic Chemistry under Prof. Xu Yuanyao.



Huiying (Harry) Li, PhD

Dr. Li is the president and CEO of Wilmington PharmaTech. He received a B.S. in chemistry from Nanjing University of Science and Technology, a M.S. in natural product chemistry from Shanghai Institute of Material Medical, Chinese Academy of Sciences, and a Ph.D. in organic chemistry from Tokyo Institute of Technology. From 1990 to 1991, Dr. Li was a post-doctoral fellow at Medical Products Department of DuPont Company. After working as a medicinal chemist with DuPont Merck Pharmaceuticals from 1991 to 1995, Dr. Li worked as process chemist at Process R&D department of DuPont Pharmaceuticals Company (1995-2001) and Bristol-Myers Squibb Company (2001-2002). He is also an **adjunct professor** of University of Delaware and Nanjing University of Science and Technology in China. Dr. Li is the author of numerous patents and publications including key process and polymorph patents related to several important pharmaceutical compounds. In 2003, he founded Wilmington PharmaTech with research labs and two cGMP facilities in Newark, Delaware. Dr. Li has also founded a R&D center with production facility in Suzhou, China.



Julius Li, MBA

Dr. Julius Li is Co-founder and CEO of AutekBio, Inc., the first therapeutic biologic CMO operating in China. In March, 2010, AutekBio signed a \$ 100M investment agreement to build the first US / EU cGMP facility in China. Prior to setup AutekBio, He was the Co-Founder and Managing Director of GoldenGate Biopharma, a biotech company specialized in cross border biotech business consulting, which licensed a US marketed antibiotics to China. Mr. Li is a professional in the commercialization of biopharmaceutical products, encompassing research, development, marketing, finance and operation.

He has taken technical and management positions in US and Chinese pharmaceutical companies, from startups to multinationals. At Guangzhou Baiyunshan Pharmaceutical Group, he led teams to launch two biochemical drugs. At Hoffmann La-Roche US division, he managed the technology transfer from development to manufacturing, and coordinated production. Mr. Li earned graduate degrees from Zhongshan University, Chinese Centers for Disease Control and Prevention (CDC) and the Ross Business School at the University of Michigan. He is also the current Deputy Director General of the National Engineering Center for Viral Biotechnology.



Evan Loh, MD, FACC, FAHA

Evan Loh, MD, FACC, FAHA is Sr. Vice President, Development and Strategic Operations (DSO), Biotherapeutics, R&D Pfizer. He is responsible for consolidating scientific and strategic inputs, providing oversight for all pre-POC development phase programs and enabling collaborative activities between key stakeholders in BioTx scientific leadership (e.g., CSOs, Clinical Programs, Pharm Sci, etc.) with BU leadership.

Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women's Hospital in Boston, MA. His clinical responsibilities included attending physician, Cardiovascular Division/Cardiac Transplantation Program and Medical Director, Heart/Lung Transplantation Program. As a faculty member at Harvard Medical School, he received National Institutes of Health (NIH) funding for his basic research interests in beta-adrenergic receptor-G-protein coupled signal transduction alterations in heart failure and denervated myocardium. He is board certified in Internal Medicine and Cardiovascular Diseases.

Prior to joining Pfizer in 2009, Dr. Loh was Vice President, Clinical Research & Development at Wyeth. He was responsible for leadership and strategic oversight of clinical development efforts across multiple therapeutic areas in Clinical Research & Development (Hematology, Oncology, Cardiovascular, Infectious Diseases, Metabolism, Immunology/Internal Medicine, and Inflammation). He also was responsible for oversight of Clinical Translational Medicine and the Medical Research group based in Japan.

At Wyeth, he was also involved in the oversight and strategic clinical development of compounds from phase 0 to IV. He is the 2006 recipient of the Heroes of Chemistry Award from the American Chemical Society for his leadership role at Wyeth for the clinical development of Tygacil, a novel glycylicline broad-spectrum antibiotic. His interests in enterprise-wide strategic change on behalf of Wyeth R&D has included leadership roles for: 1) design and implementation of the Learn and Confirm Clinical Development model; 2) Project Impact Research Optimization Initiative; and 3) R&D TA/DA Optimization project.

In 2000, Dr. Loh was Associate Professor of Medicine at the University Of Pennsylvania School of Medicine. His clinical responsibilities included Medical Director, Heart Failure & Cardiac Transplantation Program; Director, Coronary Care Unit; and Interim Division Chief, Cardiovascular Medicine at the University of Pennsylvania Health System. In 1996, he was named one of the 50 most positive physician role models in the United States. His clinical research interests included studies in predictors of survival in patients with heart failure, mechanisms of pulmonary vascular control in humans, and molecular epidemiology approaches to the identification of disease-modifying loci in subjects with heart failure. He has published more than 100 peer-reviewed articles, multiple review articles/book chapters and has edited a book entitled, "Heart Failure: A Clinician's Guide to Ambulatory Diagnosis and Treatment" (vita attached). He has served as a reviewer for multiple peer-reviewed journals including the New England Journal of Medicine, Circulation, The Journal of the American College of Cardiology, Circulation Research, and JAMA. He is a Fellow of the American College of Cardiology and Fellow of the American Heart Association.



Ronald L. Panitch, Managing Partner

Ronald L. Panitch is a founding partner of Panitch Schwarze Belisario & Nadel. His practice focuses on licensing and counseling in both patent and trademark matters.

Mr. Panitch has extensive experience in negotiating and designing creative settlements for issues that are difficult to resolve in contested proceedings. He is frequently asked to appear as an expert witness in contested proceedings. From 1999 to December 2007 Mr. Panitch was a partner of Akin Gump Strauss Hauer & Feld where he served on the management committee and was the Partner in Charge of the Philadelphia Office of Akin Gump.

Prior to joining Akin Gump, Mr. Panitch was a founding partner of Panitch Schwarze Jacobs & Nadel, P.C. He served as managing partner of the firm from its creation in 1983. Previously, he was engaged in private practice in Philadelphia. Mr. Panitch began his career in 1962 at the United States Patent and Trademark Office, where he worked as a patent examiner while attending law school.

Mr. Panitch received his B.S.M.E. in 1962 from the New Jersey Institute of Technology, from which he received the 2001 Alumni Achievement Honor Roll Medal for "outstanding achievement in intellectual property law." He received his LL.B. in 1965 from Georgetown University, where he was associate editor of the *Georgetown Law Journal*. Mr. Panitch is a member of the Philadelphia, Pennsylvania and American Bar Associations; the Philadelphia Intellectual Property Law Association; and the American Intellectual Property Law Association. He is registered to practice before the United States Patent and Trademark Office. He is a former member of the advisory board of the University City Science Center in Philadelphia.

Mr. Panitch has written and lectured extensively on intellectual property law. He is an elected member of the American Law Institute, and for the last decade has co-chaired ALI-ABA's annual program on Trademarks and Copyrights for the General Practitioner. He has been a guest lecturer at numerous other ALI-ABA programs in which he has taught practicing attorneys about patents, trademarks and unfair competition, and co-chaired a program entitled "Securing and Enforcing Patent Rights." He co-authored the articles "Distinguishing Patents and Trade Secrets" (*The National Law Journal*) and "It's Not Just Location: It's All In A Name!" (*The Real Estate Finance Journal*, Summer 2001).

Mr. Panitch was named in the 2004, 2005, 2006, and 2007 editions of *Chambers USA* as one of "America's Leading Lawyers for Business," in the 2006 edition of *The Best Lawyers in America*, and in the 2007 edition of *Chambers Global* "World's Leading Lawyers for Business." *Philadelphia Magazine* twice named him one of the "Best Lawyers in Philadelphia" - in 1994 and again in 1999, the two years in which the magazine published its "Best Lawyers" list.

Allen B. Reitz, PhD

Dr. Reitz has had 27 years of demonstrated accomplishment as a medicinal chemist in the pharmaceutical industry, including nearly 26 years with Johnson & Johnson. For 16 years at the Spring House, Pennsylvania facility of Johnson & Johnson he led the medicinal chemistry research effort in the area of the diseases of the central nervous system for both psychiatry and neurology. He is co-inventor as well as Team Leader, in most cases, for seven compounds that have entered human clinical trials, three of which are currently in the clinic (Phase I and II). He has ca. 130 scientific publications and 43 issued U.S. patents, and is the Editor-in-Chief of the journal *Current Topics in Medicinal Chemistry*. He has extensive experience in project and portfolio management, target validation, hit triage, hit to lead and lead optimization medicinal chemistry, eADME profiling, and preclinical candidate selection. He is also Adjunct Professor at Drexel University, College of Medicine.



Peter Tu, JD, MBA

Peter Tu is Vice President, Legal, for moksha8 Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on commercialization of pharmaceutical products in emerging markets. In that capacity, Mr. Tu heads up the global legal function and is a member of moksha8's executive management team. Mr. Tu has held a series of positions of increasing responsibility as in-house counsel for various pharmaceutical and biotech companies over the last decade. Mr. Tu started his legal career as a patent litigator in the New York office of Weil, Gotshal & Manges after serving as a law clerk for two distinguished appellate judges, Justice Stewart G. Pollock (NJ Supreme Court) and later for Judge Leonard I. Garth (Court of Appeals for the Third Circuit).

Mr. Tu graduated magna cum laude from Seton Hall Law School, where he served as the Symposium Editor for the Seton Hall Law Review. Mr. Tu also received an MBA in Finance from Seton Hall University and bachelors degrees in chemical engineering and biology from MIT.

In 2002, Mr. Tu was selected by the National Asian Pacific American Bar Association as one of the Best Lawyers Under 40 in the United States. Only twenty-five attorneys throughout the country were selected to receive this prestigious designation and award.



Mervyn Turner, PhD

Dr. Mervyn Turner joined Merck Research Laboratories in 1985. Over the last 25 years, he has held many positions of increasing responsibility at Merck. In August 1999, Dr. Turner was appointed Senior Vice President, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. Dr. Turner returned from his assignment in Montreal in October 2002 to take up the position of Senior Vice President, Worldwide Licensing and External Research. In this role, he was responsible for the oversight of all of Merck's licensing activities, and for the management of academic relations. Through his multiple and diverse experiences in the Merck Research Laboratories, Dr. Turner has acquired a broad perspective on the issues surrounding drug discovery and development.

2004 through 2008 saw a sizeable increase in deal activity for Merck, with over 190 transactions completed. Merck has also been active in M&A, with Aton, Abmaxis, GlycoFi, Sirna and NovaCardia, all acquired to build areas of key strategic importance. Dr. Turner saw all this activity as a logical product of a cultural shift within Merck towards a more outward-facing organization. In September 2008, Dr. Turner was also appointed to the newly created role of Chief Strategy Officer for Merck & Co. Inc. where he leads the formulation and execution of Merck's long term strategic plan and the linkage of that strategy to the business plans of Merck's Franchises, Divisions, and Functions. In November 2009, Dr. Turner turned over the licensing reins when, in addition to his CSO role, he was appointed Senior Vice President, Emerging Markets, Merck Research Laboratories where he is responsible for developing MRL strategy to both support our commercial aspirations in the regions, and also to leverage emergent capabilities in India and China to the global benefit of the MRL pipeline.

Dr. Turner is the author of over 80 articles in peer reviewed journals. He has served on the Editorial Board of a number of journals, and from 1998 to 2008 he was a member of Health Care Ventures Scientific Advisory Board.



Wim Vandenhouweele

Wim Vandenhouweele is Executive Director, Global Vaccine Commercial Development, Merck and Co. Inc. (PA, US). In this role, he and his team identify commercial opportunities for the Merck vaccines worldwide, as well as coordinate global tender and supply communication. Wim was born in Belgium, studied Sports-physiology at University Ghent, Belgium, Marketing at EHSAL Brussels, Belgium and IEP at INSEAD, Fontainebleau, France. Since joining Merck 26 years ago, Wim has worked in Belgium, the Netherlands and Merck's global headquarters in New Jersey. He moved to Merck (MSD) China in early 2005 as Executive Director, Marketing in Shanghai, China. In 2007, as a member of the China Executive Team, Wim became the Executive Director,

China Strategy. He also led the next phase of the China-MSD HIV/AIDS Public-Private Partnership [C-MAP] initiative, focusing on Sichuan, China, and assumed the role of National Director for C-MAP in Beijing, China. In addition, Wim served as Director for Hangzhou MSD Pharmaceutical Co., Ltd., a joint venture entity in China.



Shifang Zhang, PhD

Dr. Shifang Zhang is currently Senior Director of Sales and Marketing at GENEWIZ, Inc. He leads GENEWIZ's global strategic branding and sales efforts. He joined GENEWIZ as Scientist, and subsequently held various responsibilities as Manager/Director of Molecular Biology, and Director of Sales and Business Development.

Prior to GENEWIZ, Dr. Zhang was cofounder and Chief Scientific Officer of BioNano, Inc., a biotech start-up in New York City devoted to developing and commercializing ultrasensitive biosensors. The research was funded by and conducted at Columbia University.

Dr. Zhang received his BS in Physiology and Biophysics from Peking University and his PhD in Genetics and Molecular Biology from Columbia University.



Zhenping Zhu, MD, PhD

Dr. Zhenping Zhu has been working in the area of antibody technologies and biotherapeutics for about 25 years. Dr. Zhu joined Novartis Biologics as Vice President and Global Head, Protein Sciences and Design, in February 2009. He has the overall responsibility for the discovery and design of novel biologic drugs, including monoclonal antibodies, recombinant proteins and engineered molecules that address diseases of high unmet need. Prior to joining Novartis, Dr. Zhu spent over 12 years at ImClone Systems as Vice President of Antibody Technology and Immunology, and has successfully led research teams that discovered and engineered 7 novel antibodies that are currently in clinical development for various oncology indications. Dr. Zhu has published over 170 peer-reviewed scientific articles, including original research papers, invited reviews and book chapters.

Dr. Zhu earned his medical degree from Jiangxi Medical College and his MS in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College. He received his PhD in Immunology and Pathology from Dalhousie University, and performed his postdoctoral work in antibody/protein engineering at Genentech Inc.



Lily Zou, PhD, MBA

Dr. Lily Zou is Senior Director, Business Development and Licensing, Specialty, at Sandoz, Inc., a subsidiary of Novartis. Sandoz is a world leader in the generics industry and a pioneer in the biosimilars space, with approximately 1000 generics in over 130 countries. Dr. Zou is responsible for business development for biosimilars and other specialty fields. She leads activities in sourcing, evaluating, negotiating and executing partnership deals to fuel the growth of Sandoz's biosimilar and specialty portfolio.

Prior to joining Sandoz, Dr. Zou was Director of Business Development at ArQule, a biotech company in greater Boston. In this role, she led business development and alliance management activities, including the execution of ArQule's \$560M partnership for the phase II c-Met inhibitor cancer drug and a \$265 M research collaboration for ArQule's kinase inhibitor platform. Previously, she held business development, strategy and portfolio management positions at Wyeth, Bristol-Myers Squibb, and Coley Pharmaceutical Group (acquired by Pfizer). She also spent 3 years in management consulting with Bain & Co, advising various pharma and biotech clients on growth, R&D and M&A strategies. Dr. Zou holds a Ph.D. in Microbiology and Immunology from Cornell University, MBA from MIT Sloan School of Management, and B.S in Biology from Beijing University.

Conference Partners



Sponsor of the Year



Gold Sponsor



Conference Sponsors



Job Opportunity Posting



WE ARE DETERMINED TO SERVE YOU BETTER®

Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical and medical device outsourcing company with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services across the discovery-to-commercialization spectrum.



药明康德
WuXi AppTec
An Integrated R&D Service Company

- Structural Biology
- X-Ray Crystallography
- Medicinal Chemistry
- Synthetic Chemistry
- Discovery Biology
- Pharmacology
- ADME - DMPK
- GLP Bioanalytical Services
- Process R&D
- Formulation
- Analytical R&D
- GMP Manufacturing
- Non-GLP and GLP Toxicology



- Biocompatibility Testing (in vivo and in vitro)
- Custom Device and Materials Testing
- Combination Products Testing
- Lot Release and Raw Materials Testing
- Sterilization Validation
- Chemistry Testing
- Microbiology Testing
- Package Testing
- Controlled Environment Testing
- Contract Manufacturing for Device, Combination and Tissue Products
- Technology Transfer
- Product Characterization
- Cell Line Engineering and Construction
- Cell Line Characterization
- GMP Cell Banking
- Cellular Therapeutics Manufacturing
- Lot Release and Raw Materials Testing
- Viral Clearance Validation
- Stability Studies
- Assay Development / Custom Assays





Services
in China



Services
in U.S.



A Full-service Platform for Clinical Research with Global Standards and China Speed:

Under the leadership of the Ministry of Science & Technology of PRC & Shanghai Municipality as a 3rd-party full-service platform, Shanghai Clinical Research Center (SCRC) helps your drug development moving faster through the "China Clinical Express".

With our unique governmental resources, the management team with intensive international experiences, and the GCP complied site network nationwide, we are pursuing a better way to meet your challenging needs for quality services in Clinical Research. .

Vision

To be one of the top clinical research centers in Asia Pacific.

Total Solutions—One-stop and Tailor-made Services

- Clinical Research Management and Site Management
- A hospital network with over 50 GCP complied site in China
- A 56-bed Phase I Unit Based in Shanghai
- An Independent Ethics Committee
- Regulatory Affairs and Medical Writing
- OC based Data Management, Biostatistics with SAS
- Central Laboratory services with CAP guidance
- Bio-bank services for translational medicine
- Clinical Research Training

Building 10, No.140 Tianlin Road, Shanghai 200233, P.R. China
 Tel: (+86-21) 33676666 Fax: (+86-21) 33676373
 Email: info@scrcnet.org <http://www.scrcnet.org>



Phase I Unit



Independent Ethics Committee



Central Laboratory

About SCRC (Shanghai Clinical Research Center)

SCRC is a full –service platform for clinical research with global standard and china speed. Under the leadership of the Ministry of Science & Technology of PRC & Shanghai Municipality as a 3rd-party full-service platform, SCRC is dedicated to make drug development more efficient. And SCRC is developing a core resources platform covering most of the clinical research sites nationwide.

With our unique governmental resources, the management team with intensive international experiences, and the GCP complied site network nationwide, we are pursuing a better way to meet our client's challenging needs for quality services in Clinical Research.

Total Solutions for drug development—One-stop and Tailor-made Services

Clinical Research Management and Site Management; A hospital network with over 50 GCP complied site in China; A 56-bed Phase I Unit Based in Shanghai; An Independent Ethics Committee led by UNESCO members; Regulatory Affairs and Medical writing; OC based Data Management and Biostatistics; Central Laboratory services with CAP guidance; Bio-bank services for translational medicine; Clinical Research Training.

Position 1: Business Development Director

The BD Director will report directly to Vice President. He/She has to develop overall BD and marketing strategy and execute strategic initiatives to support SCRC's success. He/she has to drive business growth and keep close partnership with desired clients to meet or exceed revenue targets.

Responsibilities:

Develop and implement BD and Marketing plans in support of organizational strategy and objectives; Meet BD plan objectives and organizational expenditure requirements in conjunction with Business Development Department; Identify, build, and manage long-term relationships with strategic partners and clients; Seek new opportunities to expand business with new clients; Initiate specific business proposals with potential clients and take a personal lead in subsequent negotiations; Establish effective communications with appropriate executives, managers and clients to understand their needs; Motivate, manage, train and develop business development and marketing team.

Qualifications:

Bachelor degree or above in clinical medicine, life science, pharmacy or business; 10+ years of experience in marketing or sales, and 5+ years at the director level; Specific expertise in CRO and clinical services is a plus; Fluency in both English and Mandarin; Excellent communication skills; Self-driven, results-oriented with a positive outlook; Proven record of success in sales & marketing is highly desirable.

Position 2: Bio-bank Director

The director is responsible for building sample library, sample donation, storage and service system with high-quality ethical standard. And the director will also be responsible for establishing sample library and donations service system with famous hospitals. He or she will report to Vice-president.

Responsibilities:

Develop more hospitals to become members of our Bio-bank; Ensure more and more qualified samples added to the sample library; Promote the cooperation between research institutes and Bio-bank members; Accomplish the operation outline of Bio-bank and report it to the Ministry of Health and the Ministry of Science and Technology successfully; Participate in international exchange meetings, raise international profile of SCRC and seek good international cooperation projects.

Qualifications:

A Master or equivalent advanced degree preferably in clinical medicine, molecular biology or relevant; Minimum of 5 years of related working experience; Fluency in both English & Mandarin; Good communication skills.

Position 3: Medical Director

The Medical Director is an employee of SCRC based in Shanghai. He/ she is accountable for achieving delivery of milestones of the clinical component of the project in accordance with contracted scope of work, budgeted hours and timelines ensuring maximum efficiency and profitability. He/ she is responsible for forming the clinical team, planning and monitoring the tasks for the clinical team, ensuring that the needs of the clinical team and individuals are met. The position will report to Vice-president.

Responsibilities:

Set-up, plan, implement and deliver the Project in accordance with the scope of work agreed with the sponsor as outlined in the Project Plan; Building a team based on the business need; Be responsible for the team member training; Track and supervise project progress, identifying and evaluating project risks throughout the project life cycle and taking advice from Senior Management on corrective action as appropriate; Communicate project progress to the Sponsor on a regular basis; Coordinate preparation of written status reports on team activities and project progress; Ensure that all deliverables are of the highest standards and meet Sponsor's expectations; Keep Senior Management fully informed of any project issues that may impact on the quality and timelines of project delivery to the Sponsor's satisfaction; Approve release of all project deliverable to the Sponsor; Conduct an 'End of Project' Review meeting to ensure that all project activities have been completed in full and ensure that Senior Management are informed of any key learning points for the future and any proposed corrective actions; Monitor QA and Update company SOPs.

Qualifications:

A Master or equivalent advanced degree preferably in Medical Science; Minimum of 10 years of clinical research experience in the biomedical or contract research organization industry required; At least 5 years of relevant working experience in Clinical Trials; Fluency in both written and oral English & Mandarin; Hands on experience in International environments; Good communication and drafting skills.

Position 4: Training Director

According to the international and professional service standard, the director will be responsible for providing training services for local researchers, clinical study monitors, clinical research coordinators, research nurses, data managers and biostatisticians. He/ she will report to Vice-president.

Responsibilities:

To integrate long term strategic plan for training brand building; set objectives and propose budget; Establish cooperation relationship with world-renowned training organization and proactive for localization; KOL management and set up Speaker Pool in academics; To maximize resource allocation and set up KA Pool; Lead the team to execute training activities as a key category in SCRC.

Qualifications:

Master degree or above in clinical medicine, public health related, MBA is preferred; Minimum of 8-10 years of related work experience in top CRO, pharmaceutical company or global research institute; Excellent verbal and written communication skills in both English and Mandarin; Insight of potential market by region and globe; Leadership role in team and strong interpersonal communication skill; Strong sense of responsibility and dedication; Good analytical and problem solving skill; Intelligent information collection on competitors.

Please submit your candidacy to the following email address by May 15, 2010: hr@scrcnet.org

HR will take directly contact with candidates. Candidate names and profiles will remain confidential to outside.

Additional information may be provided to pre-selected candidates by 30 May, 2010.

Interviews may be held between 5 and 10 June, 2010. Our website: www.scrcnet.org



Job Opportunities at PharmaLegacy Laboratories Shanghai, China

PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty services of pharmacology in Bone/Orthopedics, Inflammation and Immune Diseases, and Oncology. PharmaLegacy management team consists of seasoned business leaders, world's renowned scholars and top service scientists from the US as well as biotech pioneers in Shanghai. With a mission to collaborate with our global clients to accelerate their effort to develop new therapies, we seek talented individuals with entrepreneurial spirits to join our exciting venture. We provide a competitive compensation package and an opportunity to thrive in a challenging and exciting biotech industry in China. We have openings for various levels of scientific positions, including scientists, senior scientists and category leaders such as Director of Inflammation and Immune Diseases, Director of Orthopedic Research.

Requirements:

Education: Ph.D. or M.D. with specialty in pre-clinical oncology, inflammation and immune diseases, molecular biology, biochemistry and bone.

Experience: Strong background in the defined categories is critical. Minimum 3 years of work experience, preferably in the biopharmaceutical industrial setting.

Personality: Mature, open and team player.

Overall Job Responsibilities of the Directors:

The position will be responsible for:

- interacting with clients to initiate and finalize outline protocols;
- taking full accountability on precise execution of the signed experimental protocol, submission of intermittent data to clients, resolution of operational schedule conflicts, documentation of modification/revisions to the study protocol, examination of data validity and analysis, interpretation of data, completion of study report, and collation and archive of study related materials according to company's policies and client's requests;
- leading/mentoring, training, coaching and delegating all direct reports (study coordinators) on project and time management;

- ensuring adhesion of project timelines by proactive scheduling with managers of operational laboratories;
- transferring technical skills and providing scientific literatures required in executing the animal models/procedures to operational staff and ensuring documentation of the transfer and the standard operation procedures;
- developing and integrating new models /assays and technology into current evaluation system;
- being responsible for contributing to the preparation and submission of invention disclosures, and patent applications, to secure intellectual property;
- aiding or writing technical reports or manuscripts to peer-reviewed journals;
- initiating and managing internal collaborative projects.

To apply in confidence please email: careers@pharmalegacy.com.

For more information, please visit our website at: www.pharmalegacy.com



Job Opportunities at Wilmington Pharma Tech

Director of Process Chemist

The candidate will direct and manage our ongoing large scale production projects. The candidate will be expected to undertake the manufacture of APIs and/or their intermediates at multi-kilo to full production scale. An outstanding record of solving complex synthetic challenges combined with demonstrated hands-on ability to execute these processes at scale is required. Perform periodic audits of areas, and work with clients and managers to develop project plans. Experience in CMC and DMF documents preparation is desired. This position requires a PhD in Synthetic Organic Chemistry, with relevant industrial experience. The candidate needs to demonstrate a high level of technical ability, scientific creativity, teamwork and independence. Strong communication skills are essential.

Senior Process Chemist

The candidate will design and perform experiments in order to develop chemical processes for the manufacture of drug substances. The candidate will be expected to subsequently undertake the manufacture of these API processes at kilo-lab scale and support manufacture in pilot production as appropriate. An outstanding record of solving complex synthetic challenges combined with demonstrated hands-on ability to execute these processes at scale is required. This position requires a PhD in Synthetic Organic Chemistry, with 0-4 year relevant industrial experience. The candidate needs to demonstrate a high level of technical ability, scientific creativity, teamwork and independence. Good communication skills are essential.

Organic/Analytical Chemist

The candidate will be responsible for method development, validation & implementation, analytical impurity synthesis & QC in support of cGMP synthesis; assist in writing of SOPs, protocols & reports; keep accurate documentation in accordance with cGMP regulations. MS in organic chemistry. Strong organic & analytical chemistry skills & strong problem solving ability req'd.



Analytical Services Job Openings at Frontage

Group Leader - Job Code: AS10-2

Responsibilities:

- Manages the assigned analytical projects to support product development. Provides updates, resolves any unexpected issues, and ensures agreed timelines.
- Prepares and/or reviews analytical test method, method validation protocol, method validation report, test protocols, test reports, stability protocol, stability reports, deviations/variances, Out-of-Specification (OOS) investigation reports and SOPs.
- Evaluates and resolves analytical and instrumental issues. Hands-on experience with HPLC, UPLC, GC, LC/MS, IC, and Dissolution testing.
- Supervise a team of junior chemists and review their notebook and data packages. Provides technical guidance to lab staff and trains staff on new instruments and technologies.

Qualifications:

- Ph.D. with a minimum of 5 years or M.S. with 8+ years relevant experience in pharmaceutical/biotech or related industry
- Excellent oral and written communications skills
- Capable of setting priorities based on a fast-paced, changing environment
- Independent decision-making required to carry out day-to-day functions
- CRO experience is a plus

Senior Scientist - Job Code: AS10-4

Responsibilities:

- **Leads** the assigned analytical projects to support product development. Provides updates, resolves any unexpected issues, and ensures agreed timelines.
- Prepares and/or reviews analytical test method, method validation protocol, method validation report, test protocols, test reports, stability protocol, stability reports, deviations/variances, Out-of-Specification (OOS) investigation reports, and SOPs.
- Evaluates and resolves analytical and instrumental issues. Hands-on experience with HPLC, UPLC, GC, LC/MS, IC, and Dissolution testing.

Qualifications:

- Ph.D. with a minimum of 2 years or M.S. with 5+ years relevant experience in pharmaceutical/biotech or related industry
- Excellent oral and written communications skills
- Capable of setting priorities based on a fast-paced, changing environment
- Independent decision-making required to carry out day-to-day functions
- CRO experience is a plus

Please email your resume and salary requirement to dwang@frontagelab.com



Position available: PhD Molecular Biologist for Project Management in South Plainfield, NJ

Description:

GENEWIZ, Inc. is a global Contract Research Organization and specializes in DNA sequencing, gene synthesis, molecular biology, and genomic services. We help scientists worldwide speed up their research progress through our distinctive combination of fast, reliable service, specialized expertise, competitive pricing, and friendly customer support. Our US headquarter is in South Plainfield, NJ with satellite facilities in La Jolla, CA, Germantown, MD, and Cambridge, MA. Our China headquarter is in Suzhou with a local laboratory in Beijing.

GENEWIZ is seeking an experienced PhD molecular biologist to join our project management team in our NJ headquarter. The ideal candidate should be experienced with a wide range of molecular biology methodologies, including gene synthesis and cloning, PCR techniques, DNA sequencing, genotyping, SNP discovery and analysis, and protein expression. Diverse technical knowledge and previous experience with sequence analysis programs, databases, and customer service are strongly preferred.

Requirements

The position requires the ability to multitask and meet deadlines in a fast-paced, customer-oriented environment. Ideal candidates must be motivated, organized, and disciplined, with excellent record keeping skills and a superb attention to detail. Strong oral and written communication skills are essential.

Qualifications

PhD in Molecular Biology or related disciplines.


Please send your resume with a cover letter to hr@genewiz.com.



eVenus Pharmaceutical Laboratories Inc, a wholly owned subsidiary of **Jiangsu Hengrui Medicine Co, Ltd**, was established in the United States in 2009. Our business is focused on filing regulatory applications with the US FDA, providing high service, quality and affordable drug substances and drug products, and developing generic and brand product portfolio.

Though a relatively new company in the US market, our parent Jiangsu Hengrui Medicine Co has a large presence in the global API supplies, including relationships with major international pharmaceutical companies. Based on a manufacturing and development history that spans over 40 years, our experience, knowledge, and capability affords us the ability to have one of the aggressive DMF and finished product pipelines in the industry. Over the next four years we will be filing an average of five additional products and DMFs per year.

Our product portfolio has a wide range of therapeutic areas including cardiovascular, CNS, oncolytic, antidiabetic, and hospital products. Dosage forms include tablets and capsules, injectables, inhalants, and nasal sprays. eVenus drug product will be marketed to chains, wholesalers, distributors and government agencies, as well as in health systems and oncology settings. Our APIs will be marketed to drug manufacturers in North America.



SunTen Phytotech (STPT), an herbal-based biotechnology company in Taiwan, is striving to unravel the miracle of nature to develop novel botanical medicine and functional dietary products. Since the company was founded in 2001, SunTen's R&D team has successfully developed a number of proprietary botanical products now under animal testing and human clinical trials. STPT believes that in such medicinal plants lie tomorrow's new drugs and the hope of millions of disease sufferers worldwide. With core competence, our product development strategy hence focuses on unmet medical demands of specific disease populations, including cardiovascular diseases, allergic asthma, chronic gastrointestinal disorders, and skin diseases for both therapeutic and health promoting remedies.

Strength

- Over 60 yrs' research experience in Traditional Chinese Medicine (TCM).
- Product candidates from reliable botanical sources.
- Risk evaluation and control system to ensure success in product development.
- Profound knowledge in current drug development process.
- Experience in developing global botanical drugs.

Approach

- Focus on unmet medical need with a defined niche market.
- Select traditional herbal medicine with long experience in human use for development.
- Apply modern development process on botanical compositions and extract isolates.
- Develop novel botanical drugs for disease therapy and health promotion.
- Establish international alliances for global product development and marketing.

Business Model

- Construct modernized technical platforms for the research and development of botanical drugs.
- Develop novel botanical drugs and its related functional dietary products with proven safety and efficacy.
- Seek out for partners with experiences in global product development.

Actively recruiting the following positions:

Chief Scientific Officer, Chief Operation Officer, Vice Presidents, and Directors

SPAP-GP Annual Conference 2010 Organizing Committee

Tsang-Bin Tzeng (Co-Chair)

Jingsong Wang (Co-Chair)

Jianguo An

Chang Bai

Zhibiao Fu

Jian He

Ming He

Laura G. Hong

Weihong Hsing

Zak Huang

Tao Jiang

Yang Jin

Mabel Ju

Lee Kang

Wensheng Lang

Jian Li

Jiangfan Li

Kai Li

Li Li

Bo Liang

Yin Liang

Frank Liu

Roger (Feng) Luo

Peter (Peizhi) Luo

Wenfang Miao

Xi (Sherry) Ouyang

Wendy Pan

Yu Ru

Li Shi

Joan (Huaqiong) Shen

Haisong Tan

Deana F Wang

Xinkang Wang

Guosheng Wu

Zhongren Wu

Li Yan

Helen Yang

Jing Yang

Ray Yin

Hancheng Zhang

Sean Zhang

Yun Zhang

Zhongda Zhang

Hua (Marlon) Zhong

De-Min Zhu

- Brochure Art Design: Jingsong Wang
- Brochure Editing: Jingsong Wang, Peter Luo, Xiaohong She
- For comments and suggestions on this and future events of SAPA-GP, please contact
Jingsong Wang, MD
610-209-8736
jwang_md@yahoo.com